Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation

Human epidermal growth factor (HER) 2-directed therapy is the standard treatment for HER2-positive breast cancer. Patients who achieved a pathological complete response (pCR) to the therapy are associated with excellent disease-free survival. However, few molecular markers are available to predict p...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujii, Satoshi, Yamashita, Satoshi, Yamaguchi, Takeshi, Takahashi, Masato, Hozumi, Yasuo, Ushijima, Toshikazu, Mukai, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386667/
https://www.ncbi.nlm.nih.gov/pubmed/28186977
http://dx.doi.org/10.18632/oncotarget.15118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386667/
https://www.ncbi.nlm.nih.gov/pubmed/28186977
http://dx.doi.org/10.18632/oncotarget.15118

Ejemplares similares